NCT05394285 2026-04-06
A Clinical Study of Hetrombopag Olamine Tablets for Thrombocytopenia Induced by Anti-tumor Treatment in Advanced Breast Cancer
Henan Cancer Hospital
Phase 2 Completed
Clinical Trials
12 trialsNCT07492693 2026-03-25
Efficacy and Safety of Hetrombopag in Preventing Chemotherapy-induced Thrombocytopenia in Gastrointestinal Tumors
Changhai Hospital
Phase 2 Recruiting
NCT07408648 2026-02-13
A Clinical Study on the Efficacy and Safety of Hetrombopag in the Treatment of Thrombocytopenia Induced by Gynecological Tumor Therapy
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2 Not yet recruiting
NCT07334093 2026-01-12
A Study of Hetrombopag Combined With rhTPO in the Treatment of Cancer Therapy-induced Thrombocytopenia (CTIT) in Solid Tumor Patients.
Sun Yat-sen University
Phase 2 Not yet recruiting
NCT06818916 2025-12-03
Hetrombopag in Promoting Platelet Engraftment After Auto-HSCT in Children With Neuroblastoma
Beijing Children's Hospital
Phase NA Recruiting
NCT07101627 2025-08-03
A Prospective, Multicenter Clinical Study of Hetrombopag in the Prevention of Thrombocytopenia Caused by Lung Cancer Therapy
Shanghai Pulmonary Hospital, Shanghai, China
Phase 2 Not yet recruiting
NCT03976882 2025-05-16
Hetrombopag for the Treatment of Chemotherapy-Induced Thrombocytopenia in Subjects With Malignancy.
Jiangsu HengRui Medicine Co., Ltd.
Phase 3 Completed
NCT05864014 2025-04-16
Hetrombopag for the Treatment of Chemotherapy-Induced Thrombocytopenia in Adults With Solid Tumors.
Jiangsu HengRui Medicine Co., Ltd.
Phase 3 Active not recruiting
NCT05442632 2024-03-13
Efficacy and Safety of Herombopag in Patients With Thrombocytopenia Before Hepatectomy
Fudan University
Phase 2 Unknown
NCT06099925 2023-10-25
The Efficacy and Safety of Hetrombopag as Secondary Prevention to Chemotherapy-induced Thrombocytopenia in Patients With Gynecologic Malignancies
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2 Unknown
NCT05261646 2023-09-28
A Clinical Study of Hetrombopag Olamine Tablets in Adults Receiving 21-day Cycles of Chemotherapy for Solid Tumours, Who Are Delayed for at Least 1 Week From Their Scheduled Cycle Because of Chemotherapy-induced Thrombocytopenia
Jiangsu HengRui Medicine Co., Ltd.
Phase 3 Withdrawn
NCT06036966 2023-09-14
The Efficacy and Safety of Hetrombopag in Primary Prevention of Thrombocytopenia Induced by the Niraparib Maintenance in Advanced Ovarian Cancer Patients
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2 Unknown